Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | -- | 3.91M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -- | 48.06M | |
| Operating Income | -- | -- | -- | -48.06M | |
| Income Before Tax | -- | -- | -- | -50.61M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -- | -50.61 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -- | -50.61M | |
| EBIT | -- | -- | -- | -48.06M | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -- | -- | -- | -35.56 | |
| Normalized Basic EPS | -- | -- | -- | -22.22 | |
| EPS Diluted | -- | -- | -- | -35.56 | |
| Normalized Diluted EPS | -- | -- | -- | -22.22 | |
| Average Basic Shares Outstanding | -- | -- | -- | 10.44M | |
| Average Diluted Shares Outstanding | -- | -- | -- | 10.44M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |